Feng Pan

Feng Pan is a seasoned professional with a robust background in health economics research and the life sciences industry. With over 15 years of experience in health economics research and more than 10 years in life sciences, Feng brings a wealth of expertise to the table. His scientific proficiencies encompass economic modeling, health care cost analysis, outcome research, economic evaluations in clinical trials, and indirect treatment comparisons. Feng's disease expertise spans across various areas including oncology (breast cancer, renal cell carcinoma, prostate cancer, melanoma, lung cancer, hematology), cardiovascular disease, arthritis (rheumatoid arthritis, psoriatic arthritis, juvenile arthritis), psoriasis, and multiple sclerosis. He also has a strong background in preparing health technology assessment (HTA) submissions. Feng holds a Ph.D. in Health Service Research and Economics from the University of Michigan, complemented by a Bachelor of Arts in Economics from Nankai University. Throughout his career, Feng has held key positions in prestigious organizations. Currently serving as the Senior Director of Health Economics at The Janssen Pharmaceutical Companies of Johnson & Johnson, he has previously worked as the Director of Health Economics at the same company. Prior to his roles at Johnson & Johnson, Feng contributed his expertise as a Research Scientist at Evidera (formerly United BioSource Corporation), and held positions as a Senior Research Associate and Research Associate III at United BioSource Corporation.